{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Transplant+1+and+2+Thalidomide", "query": { "intervention": "Transplant 1 and 2 Thalidomide" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Transplant+1+and+2+Thalidomide&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T13:41:35.644Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00064337", "title": "S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Plasma Cell Myeloma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 104, "start_date": "2004-01", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2018-08-09", "last_synced_at": "2026-10-01T13:41:35.644Z", "location_count": 35, "location_summary": "Little Rock, Arkansas • Sacramento, California • Boise, Idaho + 19 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Boise", "state": "Idaho" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Salina", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00064337" }, { "nct_id": "NCT00792142", "title": "Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm", "Neurotoxicity" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" }, { "name": "cytogenetic analysis", "type": "GENETIC" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 45, "start_date": "2008-01-16", "completion_date": "2014-04-21", "has_results": true, "last_update_posted_date": "2021-08-19", "last_synced_at": "2026-10-01T13:41:35.644Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00792142" }, { "nct_id": "NCT00577096", "title": "Effects of Exercise in Combination With Epoetin Alfa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Epoetin Alfa", "type": "DRUG" }, { "name": "Exercise", "type": "BEHAVIORAL" }, { "name": "Autologous Peripheral Blood Stem Cell Transplantation", "type": "BIOLOGICAL" }, { "name": "Red Blood Cell Transfusion", "type": "BIOLOGICAL" }, { "name": "Thalidomide", "type": "DRUG" }, { "name": "Heparin, Low-Molecular-Weight", "type": "DRUG" }, { "name": "Platelet Transfusion", "type": "BIOLOGICAL" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Total Therapy II", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BEHAVIORAL", "BIOLOGICAL" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 120, "start_date": "2001-10", "completion_date": "2004-06", "has_results": true, "last_update_posted_date": "2015-04-06", "last_synced_at": "2026-10-01T13:41:35.644Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00577096" }, { "nct_id": "NCT00083551", "title": "UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Thalidomide", "type": "DRUG" }, { "name": "Ara-C", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cytoxan", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Recombinant GM-CSF", "type": "DRUG" }, { "name": "Interferon-alpha-2b", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 668, "start_date": "1998-08", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2015-11-23", "last_synced_at": "2026-10-01T13:41:35.644Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00083551" }, { "nct_id": "NCT00081939", "title": "UARK 2003-33, Total Therapy III", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Velcade", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 303, "start_date": "2004-01", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2017-10-17", "last_synced_at": "2026-10-01T13:41:35.644Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00081939" }, { "nct_id": "NCT00006890", "title": "Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "prednisone", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NCIC Clinical Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "16 Years to 120 Years" }, "enrollment_count": 67, "start_date": "2000-07-12", "completion_date": "2008-12-15", "has_results": false, "last_update_posted_date": "2020-04-02", "last_synced_at": "2026-10-01T13:41:35.644Z", "location_count": 1, "location_summary": "Duluth, Minnesota", "locations": [ { "city": "Duluth", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006890" }, { "nct_id": "NCT01661400", "title": "Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Neuroectodermal Tumors, Primitive", "Wilms Tumor", "Rhabdomyosarcoma", "Sarcoma, Ewing", "Osteosarcoma", "Retinoblastoma" ], "interventions": [ { "name": "Metronomic Cyclophosphamide", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Months to 21 Years" }, "enrollment_count": 14, "start_date": "2012-10-26", "completion_date": "2023-12-27", "has_results": false, "last_update_posted_date": "2024-01-31", "last_synced_at": "2026-10-01T13:41:35.644Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01661400" }, { "nct_id": "NCT03411031", "title": "Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-10-04", "completion_date": "2021-11-04", "has_results": true, "last_update_posted_date": "2023-03-29", "last_synced_at": "2026-10-01T13:41:35.644Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03411031" }, { "nct_id": "NCT07247097", "title": "ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Newly Diagnosed Multiple Myeloma", "Transplant Ineligible", "Newly Diagnosed Multiple Myeloma (NDMM)" ], "interventions": [ { "name": "Elranatamab (PF-06863135)", "type": "DRUG" }, { "name": "Daratumumab and Hyaluronidase-fihj", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bortezomib for Injection", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2026-08-01", "completion_date": "2035-12-01", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-01T13:41:35.644Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07247097" }, { "nct_id": "NCT00004088", "title": "Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "pamidronate disodium", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 77, "start_date": "1999-04-13", "completion_date": "2018-01-09", "has_results": true, "last_update_posted_date": "2019-07-02", "last_synced_at": "2026-10-01T13:41:35.644Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Duarte, California", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004088" } ] }